Fragment Design

Fragment Design
Name	Fragment Design
Type	Methodology
Industry	Pharmaceutical research
Founded	1990s
Founder	Erick Lindahl
Headquarters	Cambridge, Massachusetts
Products	Fragment libraries, screening platforms

Fragment Design Fragment Design is a medicinal chemistry strategy that uses small, low-molecular-weight chemical fragments to identify and optimize ligands for biological targets. Originating alongside advances in structural biology and biophysics, Fragment Design integrates techniques from X-ray crystallography, nuclear magnetic resonance spectroscopy, high-throughput screening, and structure-based drug design to create leads for therapeutic development. The approach has been applied across collaborations involving institutions such as GlaxoSmithKline, AstraZeneca, Novartis, and academic centers like University of Cambridge and Massachusetts Institute of Technology.

Overview

Fragment Design centers on assembling and elaborating minimal scaffolds derived from fragment libraries to bind proteins, enzymes, receptors, or nucleic acid motifs. Influential projects at organizations like Pfizer, Eli Lilly and Company, and Roche demonstrated how fragment-derived ligands progressed into clinical candidates, complementing parallel methods used at Scripps Research, Dana-Farber Cancer Institute, and Harvard Medical School. The strategy leverages information from structural efforts exemplified by work at European Molecular Biology Laboratory, Diamond Light Source, and Brookhaven National Laboratory to guide chemical elaboration.

Principles and Methodology

Core principles include starting with low molecular weight (<300 Da) fragments, emphasizing ligand efficiency metrics developed in studies at Glaxo and scholarly centers, and using iterative cycles of design, synthesis, and structural validation. Methodological pillars trace intellectual roots to techniques validated by groups at Imperial College London, Max Planck Society, and University of California, San Francisco. Practitioners integrate inputs from experiments run at facilities like Stanford Synchrotron Radiation Lightsource and computational analyses common at European Bioinformatics Institute.

Fragment Screening Techniques

Screening techniques combine biophysical assays and structural determination. Common experimental modalities include X-ray crystallography campaigns at beamlines affiliated with Diamond Light Source and Advanced Photon Source, NMR spectroscopy implemented with instruments from Bruker Corporation, and surface-based methods such as surface plasmon resonance utilized in labs at Biacore partners. Other approaches employ thermal shift assays refined by groups at University of Oxford and mass spectrometry workflows advanced at Cold Spring Harbor Laboratory.

Hit-to-Lead Optimization

Hit-to-lead workflows rely on fragment growing, linking, and merging strategies demonstrated in medicinal chemistry programs at Merck & Co., Bayer AG, and Johnson & Johnson. Structural snapshots from collaborations with research hubs like Lawrence Berkeley National Laboratory or academic teams at University of Toronto inform stepwise elaboration to improve potency, selectivity, and ADMET profiles assessed in CROs and institutions including Charles River Laboratories and CRO Contract Research Organization networks. Optimization frequently references success stories from alliances between University of Oxford and industrial partners.

Computational Approaches

Computational methods augment experimental screening through virtual fragment docking, free-energy perturbation studies, and machine learning models developed at labs such as DeepMind, IBM Research, and groups within California Institute of Technology. Software platforms from Schrodinger, Inc., OpenEye Scientific, and academic tools emerging from European Molecular Biology Laboratory provide virtual libraries and scoring functions. Integrative pipelines combine structural ensembles from Protein Data Bank depositions and cheminformatics resources maintained at European Bioinformatics Institute.

Applications in Drug Discovery

Fragment Design has been applied across therapeutic areas including oncology programs at National Cancer Institute, antiviral campaigns influenced by work at Centers for Disease Control and Prevention, and neuroscience projects undertaken at National Institute of Mental Health. Industry-academic consortia such as those involving Wellcome Trust, Bill & Melinda Gates Foundation, and Innovative Medicines Initiative have funded fragment-based programs targeting enzymes, protein–protein interactions, and allosteric sites, with translational links to clinical trial networks coordinated by ClinicalTrials.gov registries.

Challenges and Limitations

Limitations include detecting weak, low-affinity interactions that require sensitive instrumentation available at facilities like Diamond Light Source and expensive computational resources from centers such as Oak Ridge National Laboratory. Intellectual property landscapes navigated by teams at World Intellectual Property Organization and regulatory considerations involving Food and Drug Administration influence development timelines. Scaling fragment hits into drug-like molecules remains nontrivial, often requiring multidisciplinary teams drawn from institutions like Massachusetts Institute of Technology, University of Cambridge, and industrial research labs at Novartis.

Category:Drug discovery